The company seeks to leverage the benefits of estrogen signaling to prevent age-related diseases and improve the “healthspan" as part of a new ARPA-H program.

DARE-PTB1 is a novel, investigational IVR designed to deliver bio-identical progesterone continuously for up to a 14-day period. It is being developed to reduce the risk of preterm birth in at-risk ...